Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Civamide Nasal Solution for Cluster Headache (ECH)

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified May 2014 by Winston Laboratories
Sponsor:
Information provided by (Responsible Party):
Winston Laboratories
ClinicalTrials.gov Identifier:
NCT01341548
First received: April 22, 2011
Last updated: May 15, 2014
Last verified: May 2014
  Purpose

The purpose of this study is to evaluate the safety and efficacy of intranasally administered civamide nasal solution in the prevention of cluster headaches during an episodic cluster headache period.


Condition Intervention Phase
Episodic Cluster Headache
Drug: Civamide nasal solution 0.01%
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Phase III, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group, Multicenter Evaluation of Civamide Nasal Solution 0.01% in the Prevention of Cluster Headaches During an Episodic Cluster Headache Period

Resource links provided by NLM:


Further study details as provided by Winston Laboratories:

Primary Outcome Measures:
  • The Percent Change in the Number of Cluster Headaches per Week from Baseline to Weeks 1 through 3 of the Post-Treatment Observation Period for the Modified Intent-to-Treat Population [ Time Frame: Weeks 1 - 3 of the Post-Treatment Observation Period ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The Percent Change in the Number of Cluster Headaches per Week from Baseline to Weeks 1 through 3 of the Post-Treatment Observation Period for the Intent-to-Treat and Per Protocol Populations [ Time Frame: Weeks 1 - 3 of the Post-Treatment Observation Period ] [ Designated as safety issue: No ]
  • The Percent Change in the Number of Cluster Headaches per Week from Baseline to Individual Weeks 1, 2, and 3 of the Post-Treatment Observation Period for the Modified Intent-to-Treat and the Per Protocol Populations [ Time Frame: Individual Weeks 1, 2 and 3 of the Post-Treatment Observation Period ] [ Designated as safety issue: No ]
  • The Change in the Number of Cluster Headaches per Week from Baseline to Weeks 1 through 3 and to Individual Weeks 1, 2, and 3 for the Post-Treatment Observation Period for the Modified Intent-to-Treat and the Per Protocol Populations [ Time Frame: Weeks 1 - 3 and to Individual Weeks 1, 2, and 3 for the Post-Treatment Observation Period ] [ Designated as safety issue: No ]

Estimated Enrollment: 180
Study Start Date: February 2015
Estimated Study Completion Date: July 2017
Estimated Primary Completion Date: April 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Civamide Nasal Solution 0.01% Drug: Civamide nasal solution 0.01%
20ug/dose, BID for 7 days 0.1 ml to each nostril
Placebo Comparator: Vehicle Solution Drug: Civamide nasal solution 0.01%
20ug/dose, BID for 7 days 0.1 ml to each nostril

Detailed Description:

This is a double-blind, randomized, vehicle-controlled, parallel-group, multi-center, phase III efficacy and safety study of civamide nasal solution 0.01% in the prevention of cluster headaches during an episodic cluster headache period. Approximately 180 subjects (about 90 per treatment group),will be enrolled and randomized to double-blind treatment with either civamide nasal solution 0.01% or vehicle solution at approximately 50 study sites with about 2-5 subjects randomized per enrolling site.

This study consists of four periods beginning with a Screening Period, lasting for a minimum of 1 day to a maximum of 12 months, during which a subject previously diagnosed with episodic cluster headaches is not experiencing cluster headaches and is awaiting the onset of their next episodic cluster headache period and subsequent enrollment. The Screening Period is followed by a 31-day study, consisting of a 3-day Baseline Period which may begin with the onset of an episodic cluster headache period and ends on the day prior to initiating treatment (Day -1). Subjects return for Visit 2 (Day 1, Pre-Dose) and the Treatment Period begins, consisting of seven (7) days of double-blind treatment. The Treatment Period is immediately followed by a twenty-one (21) day Post-Treatment Observation Period.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written IRB-approved informed consent has been obtained and signed, within 12 months of entering into the Baseline Period (Day -3).
  • Male or female 18 years or older.
  • Subject has ≥2 year history of episodic cluster headache with at least 2 previous episodic cluster headache periods.
  • Cluster Headaches must meet the following International Headache Society Diagnostic Criteria :

    • Severe, unilateral, orbital, superorbital and/or temporal pain lasting 15 to 180 minutes untreated.
    • Headache is associated with at least one of the following which have to be present on the side of the pain:

      • Conjunctival injection
      • Lacrimation
      • Nasal Congestion
      • Rhinorrhea
      • Forehead and facial sweating
      • Miosis
      • Ptosis
      • Eyelid edema or
      • A sense of restlessness or agitation
  • The current episodic cluster headache period is expected to last at least 5 weeks but no more than 24 weeks from the time of entry into the Baseline Period (Day -3), based on the average duration of the subject's usual episodic cluster headache period.
  • At least one cluster headache (but no more than 8) daily on each of the three days of the Baseline Period (Days -3, -2, -1) immediately preceding Study Day 1.
  • The subject is in generally good health, other than history of episodic cluster headache.
  • The subject agrees not to begin any new concurrent medications or restricted medications during their participation in study.
  • All females of childbearing potential must have a negative urine and/or serum pregnancy test prior to entry into the Treatment Period.
  • Females of childbearing potential agree to use an approved form of birth control or to abstain from sexual activity during the study.
  • Subject can read and write in the local language and can be expected to reliably follow study procedures.

Exclusion Criteria:

  • Clinical, historical or previous laboratory evidence of significant cardiovascular, renal, gastrointestinal, pulmonary, hepatic, endocrine, neurological (not including cluster headaches), psychological, or other systemic disease that, in the opinion of the investigator, might confound the results of the study or pose an additional risk to the subject.
  • Presence of a significant nasal disorder.
  • Initiation of a medication, discontinuation of a medication or a change in the regimen of existing medication(s) or therapies for prophylaxis of cluster headaches in the 17 days prior to entering the Treatment Period (Study Day 1).
  • Use of systemic steroids to treat the current cluster headache episode.
  • Use of restricted medications/treatments within the given time period prior to the Treatment Period and throughout the study (Table 1 of Protocol)
  • Subject has difficulty distinguishing his/her episodic cluster headache attacks from other types of headaches, such as tension type headaches.
  • Presence of chronic paroxysmal hemicrania, transformed migraine, or analgesic rebound headaches.
  • Females who are pregnant, breast-feeding, or planning to become pregnant during the study.
  • Subject has a history of alcohol and/or drug abuse within 12 months prior to the Screening Visit..
  • Subject has known hypersensitivity to or contraindication to the use of civamide, capsaicin, or to any excipient of the clinical formulation.
  • Subject has participated in another investigational study or taken another investigational drug within the past 4 weeks.
  • Subject has participated in prior efficacy studies of intranasal civamide: WL-1001-02-01, WL-1001-02-02, WL-1001-02-03 or WL-1001-02-05. (This does not include any subject who entered the screening period for study WL-1001-02-01, WL-1001-02-02, WL-1001-02-03 or WL-1001-02-05 but did not randomize to treatment).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01341548

Contacts
Contact: Heidi B Fezatte, BS 847-362-8200

Sponsors and Collaborators
Winston Laboratories
Investigators
Study Director: Scott B Phillips, M.D. Winston Laboratories
  More Information

No publications provided

Responsible Party: Winston Laboratories
ClinicalTrials.gov Identifier: NCT01341548     History of Changes
Other Study ID Numbers: WL-1001-02-06
Study First Received: April 22, 2011
Last Updated: May 15, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Winston Laboratories:
Nasal
Cluster Headache
Episodic Cluster
Headache
Phase 3
Civamide
TRPV-1 Receptor

Additional relevant MeSH terms:
Cluster Headache
Headache
Headache Disorders
Headache Disorders, Primary
Trigeminal Autonomic Cephalalgias
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Pain
Signs and Symptoms
Pharmaceutical Solutions
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on November 20, 2014